Synribo
| Synribo | |
|---|---|
| Term | Synribo |
| Short definition | Synribo - (pronounced) (sin-RY-boh) A drug used to treat adults with certain types of chronic myeloid leukemia that cannot be treated with tyrosine kinase inhibitors (a type of cancer drug) or who have not improved after treatment with at least two tyrosine kinase inhibitors. It is also being studied in the treatment of other types of cancer. |
| Type | Cancer terms |
| Specialty | Oncology |
| Language | English |
| Source | NCI |
| Comments | |
Synribo - (pronounced) (sin-RY-boh) A drug used to treat adults with certain types of chronic myeloid leukemia that cannot be treated with tyrosine kinase inhibitors (a type of cancer drug) or who have not improved after treatment with at least two tyrosine kinase inhibitors. It is also being studied in the treatment of other types of cancer. Synribo blocks certain proteins involved in cell growth and can kill cancer cells. It is a type of plant alkaloid and a type of protein synthesis inhibitor. Also called homoharringtonine and omacetaxine mepesuccinate
External links
- Medical encyclopedia article on Synribo
- Wikipedia's article - Synribo
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski